Biotechnology

Ajinomoto Bio-Pharma Services Introduces AJILITY Fast Track Platform for Drug Product Manufacturing

SAN DIEGO, June 30, 2020 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a leading provider of biopharmaceutical contract development and manufacturing services, is pleased to announce the launch of AJILITY™, a flexible and agile drug product manufacturing platform, designed to ...

2020-06-30 20:10 679

Thrombosis Research Institute (TRI) Announce ETHIC Trial to Evaluate the Potential Benefits of Early Administration of LMWH in Patients with COVID-19

- Clinical trial will recruit approximately 1400 patients in 10 countries starting in July  - Participants will be randomised to receive the low molecular weight Heparin enoxaparin or current standard of care for up to 3 weeks from the time of diagnosis  - The study is supported through an inve...

2020-06-30 14:00 651

AOBiome Reports Successful Clinical Trials (Phase 2a in Adults and Phase 1b in Pediatrics) in Pruritus (Itch) Associated with Atopic Dermatitis: Initiates Phase 2b Clinical Trial in Adults

AOBiome's 576 patient Phase 2b trial commences patient enrollment CAMBRIDGE, Massachusetts, June 30, 2020 /PRNewswire/ -- AOBiome Therapeutics, Inc. ("AOBiome"), a leading clinical-stage microbiome company focusing on inflammation,  announced initiation of a Phase2b clinical trial in pruritus (i...

2020-06-30 13:00 572

MedAlliance Gains CE Mark Approval for Coronary SELUTION SLR™ Sirolimus Drug Eluting Balloon

NYON, Switzerland, June 30, 2020 /PRNewswire/ -- MedAlliance has announced the award of its second CE Mark: SELUTION SLR™ 014 PTCA, a novel Sirolimus Drug Eluting Balloon (DEB), for the treatment of coronary arterial disease. This includes indications for both de-novo lesions as well as in-stent ...

2020-06-30 08:00 794

Global Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2020

Added 18,488 New Subscribers in 4Q20 4Q20 Revenues Increased by 19.2% YoY to RMB299.9 Million ($42.4 Million) 4Q20 Operating Income Increased by 68.1% YoY to RMB149.3 Million ($21.1 Million) Non-GAAP Operating Income Up 58.7% YoY to RMB161.7 Million ($22.8 Million) Conference Call to be Held on Jun...

2020-06-30 04:16 12053

RevImmune Announces Phase II Trial of the T-Cell Growth Factor CYT107 for COVID-19

Under Way in Europe Since May, In Preparation in the U.S.  Designated As An Urgent Public Health National Priority In U.K. BETHESDA, Maryland, June 29, 2020 /PRNewswire/ -- RevImmune, a privately held biotechnology company developing CYT107 immune therapy for infectious diseases and cancer, an...

2020-06-29 21:00 708

Picosun's Medical ALD Solutions Ensure Excellent Hermetic Encapsulation

ESPOO, Finland, June 29, 2020 /PRNewswire/ -- Picosun Group reports excellent results in ALD-organic bilayer encapsulation of metal electrodes for neuroprosthetics and bioelectronic medicine. Group also reports superior hermetic barrier performance of its ALD nanolaminates against corrosive ion ...

2020-06-29 11:34 681

Philogen Received Clinical Trial Authorisation With Nidlegy in Nonmelanoma Skin Cancer

SIENA, Italy, June 26, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that the Swiss national competent authority Swissmedic issued the authorization to run a clinical phase II study in patients with locally advanced, not metastatic nonmelano...

2020-06-26 15:00 953

ERBA Mannheim Launches CE Marked COVID-19 IgM Antibody ELISA

LONDON, June 25, 2020 /PRNewswire/ -- In response to the ongoing COVID-19 pandemic,Erba Mannheim today launched the ErbaLisa COVID-19 IgM ELISA kit for detection of IgM antibodies to SARS-CoV-2. IgM antibodies are produced first and detectable during disease onset, so using the new assay in comb...

2020-06-25 01:08 1474

Global Cord Blood Corporation to Report Fourth Quarter and Full Year Fiscal 2020 Financial Results

HONG KONG, June 24, 2020 /PRNewswire/ -- Global Cord Blood Corporation (NYSE: CO) (the "Company"),China's leading provider of cord blood collection, laboratory testing, hematopoietic stem cell processing and stem cell storage services, today announced that it plans to release financial results fo...

2020-06-24 19:30 13239

Philogen Received Combination Pack Approval for Nidlegy

SIENA, Italy, June 24, 2020 /PRNewswire/ -- Philogen S.p.A., a privately-owned biotechnology company, is pleased to announce that, onJan. 30, 2020, EMA's CHMP expressed a favorable opinion to the request of a combination pack for the to-be-marketed pharmaceutical form of NidlegyTM, a combination ...

2020-06-24 15:00 696

Akeso Appoints Prof. Bradley Monk as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee

LOS ANGELES, June 24, 2020 /PRNewswire/ -- Akeso, Inc. ("Akeso", 9926.HK) announced the appointment of ProfessorBradley J. Monk, MD, FACOG[1], FACS[2] as Lead Gynecologic Oncology Advisor and Chair of the Steering Committee for its global Phase 2, multicentre registration study to evaluate the ef...

2020-06-24 12:55 6061

InxMed Released Research Data of "FAK inhibitor IN10018 overcomes drug resistance of KRAS G12C inhibition" at 2020 AACR Annual Meeting

SHANGHAI, June 24, 2020 /PRNewswire/ -- InxMed (Shanghai) Co., Ltd. ("InxMed" or "Company"), a clinical stage biotech company dedicated to developing innovative, individualized medicines with international impact, announced that the company has released the research data of "FAK inhibitor IN10018...

2020-06-24 08:41 462

IgNova Files Patent Application on Antibody Against COVID-19

VISBEK, Germany, June 24, 2020 /PRNewswire/ -- IgNova announced today that it has filed a patent application covering the use of passive immunization to control SARS-CoV-2 infection in humans. IgNova, a biopharmaceutical R&D start up, researches technology based on specific egg immunoglobulins (I...

2020-06-24 02:13 845

Greater cfDNA Recovery May Help Accelerate Development of Cancer Liquid Biopsy Applications

HONG KONG, June 23, 2020 /PRNewswire/ -- PHASE Scientific, a high-growth biotechnology company that develops innovative sample preparation technologies, announced new findings at the American Association for Cancer Research (AACR) 2020 Virtual Annual Meeting II. The study presented by MD Anderson...

2020-06-23 09:00 772

Kazia Presents Further Paxalisib and Cantrixil Data at AACR, Reinforcing Positive Efficacy Signals for both Drugs

SYDNEY, June  22, 2020 /PRNewswire/ -- Kazia Therapeutics Limited (ASX: KZA; NASDAQ: KZIA), an Australian oncology-focused biotechnology company, is pleased to share poster presentations of interim data from the ongoing phase II study of paxalisib (formerly GDC-0084) in glioblastoma, the most com...

2020-06-22 12:39 3081

Qiming's Portfolio Company SinocellTech Lands on STAR Market

SHANGHAI, June 22, 2020 /PRNewswire/ -- Chinese biologic drug developer SinocellTech, Qiming's portfolio company, today lands on the Science and Technology Innovation Board (the STAR Market). The issue price of SinocellTech (SHSE: 688520) isCNY 25.64 per share. The stock opens at CNY 85 per share...

2020-06-22 12:20 793

Innovent Announces The Stock Exchange of Hong Kong Limited Approved the "B" Marker Removal from the Company's Stock Symbol in the HKEX

SUZHOU, China, June 22, 2020 /PRNewswire/ -- Innovent Biologics, Inc. (Innovent) (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of cancer, metabolic, autoimmune and other major diseases, today announc...

2020-06-22 07:40 2910

Ascentage Pharma Enters Clinical Collaboration to Evaluate the Combination of Bcl-2 and BTK Inhibitors

SUZHOU, China and ROCKVILLE, Md., June 22, 2020 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global, clinical-stage biotechnology company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and senescence diseases, today announced a clinical collaboration with Acerta P...

2020-06-22 07:15 567

Embrace Change to Turn Challenges into Opportunities: WuXi Biologics Successfully Hosted the 2nd Investor Day

SHANGHAI, June 19, 2020 /PRNewswire/ -- WuXi Biologics ("WuXi Bio") (2269.HK), a global company with leading open-access biologics technology platforms, announced that its 2nd Investor Day with the theme of "Embrace Change to Turn Challenges into Opportunities", was successfully held onJune 18. T...

2020-06-19 17:56 528
1234567 ... 68